Skip to Content
Global News Select

Vertex Pharmaceuticals Down Over 8%, Worst Performer in The S&P 500 and Nasdaq 100 So Far Today — Data Talk

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $198.12, down $18.65 or 8.6%


-- Would be lowest close since Nov. 7, 2019, when it closed at $195.83

-- On pace for largest percent decrease since Oct. 15, 2020, when it fell 20.7%

-- Snaps a three day winning streak

-- Down 5.04% month-to-date

-- Down 16.17% year-to-date

-- Down 34.63% from its all-time closing high of $303.10 on July 20, 2020

-- Down 26.23% from 52 weeks ago (June 12, 2020), when it closed at $268.56

-- Down 34.63% from its 52-week closing high of $303.10 on July 20, 2020

-- Would be a new 52-week closing low

-- Traded as low as $193.00; lowest intraday level since Oct. 28, 2019, when it hit $192.32

-- Down 10.97% at today's intraday low; largest intraday percent decrease since Oct. 15, 2020, when it fell as much as 21.47%

-- Worst performer in the S&P 500 today

-- Worst performer in the Nasdaq 100 today

-- Third most active stock in the Nasdaq 100 today


All data as of 10:32:45 AM


Source: Dow Jones Market Data, FactSet


(END) Dow Jones Newswires

June 11, 2021 10:52 ET (14:52 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.